{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The percentage of evaluable subjects who exhibited a post-baseline tumor assessment BOR rating of CR, PR, or SD per modified RECIST for MPM.","groups":[{"description":"CRS-207 and pembrolizumab were administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) was administered by IV infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 CFU) was administered by IV infusion over 1 hour on Day 2. If tolerated, pembrolizumab and CRS-207 were administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab continued to be administered on Day 1 at each treatment cycle (every 3 weeks); and CRS-207 was administered once every 6 weeks (every other cycle).","id":"OG000","title":"Experimental"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis based on subjects who received ≥1 dose of study treatment and had ≥1 evaluable post-baseline modified RECIST for MPM tumor response assessment or were discontinued due to toxicity (the Evaluable Analysis Set \\[EAS\\]). 1 subject did not have post-baseline tumor response assessments and could not be evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"BOR was assessed from the first dose of study treatment until documented disease progression, initiation of new cancer treatment, death, or study termination, whichever is earlier, assessed up to 15 weeks.","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Participants"}